Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

IRLAB signs agreement with TCTC to conduct Phase-2 study with IRL790

Development of IRLAB Therapeutics’ candidate drugs continues according to plan and an agreement has been signed with The Clinical Trial Company Ltd (TCTC) to conduct the planned Phase 2 study with the drug candidate IRL790. The study will be conducted at clinics in the UK. Thereby, IRLAB enters into Phase 2 studies with both their candidate drugs – IRL790 and IRL752 – during the autumn.The Phase 1b study regarding IRL790, which was concluded during spring 2017, provided positive and very valuable information about safety, tolerability, dosing and efficacy, supporting the planning of the

Thule presents its products for active outdoor living at the Caravan Salon in Düsseldorf, Germany, August 26 - September 3

Whether it’s exploring spectacular nature in the great outdoors or travelling the world with family and friends, we all have a passion for enjoying an active life. Thule provides the accessories for your RV that will help you bring what you care for most to fully enjoy your holiday. Come visit the Thule booth at the world’s largest RV fair to see our latest awnings, tents, bike racks, roof rack, …The Caravan Salon in Düsseldorf is the largest trade fair for the worldwide RV industry, with around 600 exhibitors and expecting over 200,000 international visitors. As one of the industry leaders

RhoVac AB’ announcement on company’s Phase I/II study

RhoVac AB ("RhoVac") announced that in January 2017, the company received the respective medicines agency and ethical committee's approval for the start of the Phase I/II study. The study started immediately and in early April 2017 the first patient was treated. Today, all 22 patients are under treatment. Company's CEO, Anders Ljungqvist, provides information on the status of the clinical study in this newsletter.At the beginning of July 2017, RhoVac announced the completion of patients’ recruitment for company's Phase I/II study in which a total of 22 people were recruited. All patients

Ericsson sues Wiko for patent infringement

· Ericsson sues smartphone maker Wiko in the regional courts of Düsseldorf and Mannheim in Germany, for infringement of patents essential for 2G, 3G and 4G cellular technology, as well as implementation patents · Wiko has been infringing Ericsson’s intellectual property rights for several years without any license or compensation, despite negotiations since 2013On August 14, 2017, Ericsson (NASDAQ: ERIC) sued smartphone maker Wiko, in the regional courts of Düsseldorf and Mannheim in Germany, for infringement of patents essential for 2G, 3G and 4G cellular technology, as well as

Results from extension study with C21 show safety, tolerability and indicate effects on lipid metabolism

Vicore Pharma AB (publ) (ticker: VICO) can today announce positive results from the Phase I extension study with its candidate drug C21.The extension study, initiated in January 2017, was performed on a group of overweight men (BMI 30-35) and with a hip to waist ratio below 0.9 but otherwise healthy. In total 16 volunteers, whereof 8 were given 100 mg C21 and 8 were given placebo during a period of 8 days participated. The aim of the study was to evaluate safety and tolerability of C21 in a group with a potentially compromised metabolic situation and to investigate if markers of metabolic

Vestas - Share buy-back programme of up to DKK 4,460 million (approximately EUR 600 million)

The Board of Directors of Vestas Wind Systems A/S has decided to initiate a share buy-back programme of up to DKK 4,460 million (approximately EUR 600 million) to be executed during the period 17 August 2017 to 29 December 2017. Together with the programme conducted earlier this year, total share buy-backs for 2017 are expected at approximately EUR 700 million.  The share buy-back programme is initiated pursuant to the authorisation granted to the Board of Directors by the Annual General Meeting on 6 April 2017, which authorises Vestas to acquire treasury shares at a nominal value not

Vestas - Interim financial report, second quarter 2017

In the second quarter of 2017, Vestas generated revenue of EUR 2,206m – a decrease of 14 percent compared to the year-earlier period. EBIT decreased by EUR 120m to EUR 279m. The EBIT margin was 12.6 percent compared to 15.6 percent in the second quarter of 2016 and free cash flow* amounted to EUR (158)m compared to EUR 330m in the second quarter of 2016.  The intake of firm and unconditional wind turbine orders amounted to 2,667 MW in the second quarter of 2017. The value of the wind turbine order backlog amounted to EUR 9.1bn at 30 June 2017. In addition to the wind turbine order

Autoliv starts collaboration with Seeing Machines to develop Driver Monitoring Systems

(Stockholm, Sweden, August 17, 2017) – Autoliv, Inc. (NYSE: ALV and SSE: ALIVsdb), the worldwide leader in automotive safety systems, will collaborate with Seeing Machines (AIM:SEE), a leader in computer vision based human sensing technologies, to develop next generation driver monitoring systems (DMS) for autonomous vehicles.According to the National Highway Traffic Safety Administration, in the United States 3,477 people were killed, and 391,000 were injured, in motor vehicle crashes involving distracted drivers in 2015 alone. The American Automobile Association also states that 21% of

Bambuser signs contract with Double Dutch

Bambuser AB (publ) ("Bambuser" or "The Company") has signed a one-year contract with Double Dutch, Inc, an event engagement company.Bambuser has signed a one-year agreement with Double Dutch for their event platform, concerning the Company's product Iris Dev. The contract, which will run over a minimum of one year, has a total license value of 235,000 SEK and additional variable revenue might occur based on usage. The agreement will be made effective from August 2017. Double Dutch is a leader in the live engagement space which powers events, conferences and trade shows and adding mobile

Interim Report period from January 2017 to June 2017

Peptonic Medical AB (publ) org nr 556776-3064 (www.aktietorget.se ticker: PMED) 2017 SECOND QUARTER (Apr-Jun) · Operating loss KSEK -2,559 (-2,770)  · Loss per share SEK -0.12 (-0.14) 2017 FIRST HALF YEAR (Jan-Jun) · Operating loss KSEK -5,240 (-6,321) · Loss per share SEK -0.25 (-0.33)IMPORTANT EVENTS DURING THE PERIOD · On March 10th, the Company announced that the primary efficacy endpoints of the first part of its phase 2b study, in which the Vagitocin® gel was investigated for the treatment of vaginal atrophy, were not met. However, further analyses of

Interim report January – June 2017

Interim report January-June 2017 · Net asset value per share at 30 June 2017 was SEK 104.09, compared to SEK 101.74 at the end of the previous year, which represents an increase of 2.3 per cent. · Bure’s net asset value was SEK 7,217M, compared to SEK 7,054M at year-end 2016. · Total return on the Bure share was -3.6 per cent, compared to the SIX Return Index which rose by 10.8 per cent. · Consolidated profit after tax was SEK 312M (364). Earnings per share amounted to SEK 4.49 (5.25). Second quarter 2017 · Net asset value per share was SEK 104.09, compared to SEK 101.

Cherry adjusts full-year forecast

All of the Cherry Group business areas are performing well but the ComeOn! integration has not yet reached a full positive impact. Thus, the Company adjusts its full-year forecast for 2017.Cherry AB (publ) shows continued strong development in all business areas with profitable growth. In December 2016, in connection with Cherry calling the option to acquire the remaining 51% of the shares in ComeOn Malta Ltd, the Group provided a forecast. The Cherry Group, together with acquired ComeOn, was estimated to generate total revenue for the full year 2017 of between SEK 2,600 and SEK 2,700

YIT brings openness to the housing markets in Prague and Bratislava

YIT CORPORATION News, August 17, 2017 at 09:30 a.m.YIT is better known in the Czech Republic and Slovakia than ever before. The company has several major projects underway in both countries. YIT has also brought Nordic openness to housing project planning. Over the past ten years, YIT has reached a solid position in the Czech and Slovak housing markets. The company’s subsidiaries in the countries are YIT Slovakia in Bratislava and YIT Stavo in Prague. “We are among the top three housing developers in the area. Our company is known for its high quality and reliability,” says Milan

Interim report, January-June 2017 Rabbalshede Kraft AB (publ)

Production for the second quarter totaled 108,381 MWh (87,664) · Net sales amounted to KSEK 49,135 (39,643) · EBITDA totaled KSEK 23,505 (9,194) · EBIT amounted to KSEK 981 (loss: 13,221) · Average income for wind-power production was SEK 453/MWh (452), of which electricity accounted for SEK 311/MWh (301) and electricity certificates and guarantees of origin for SEK 142/MWh (151)First six months, January-June 2017 · Production from the Group’s wind farms during January-June amounted to 246,440 MWh (212,050).· Net sales totaled KSEK 109,807 (94,445).· EBITDA amounted to KSEK 48,885 (

NeuroVive Pharmaceutical AB Interim report January - June 2017

Strategic in-licensing broadens the project portfolioBusiness operations Significant events April-June 2017 · The anti-fibrotic effects of NV556 in non-alcoholic steatohepatitis (NASH) was confirmed in an additional experimental model. The preclinical data was presented at The International Liver Congress™ in Amsterdam.  · At the Annual General Meeting on 27 April, two new board members were elected: Jan Törnell, adjunct Professor at the Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of Gothenburg, and David Bejker, CEO of Affibody Medical AB  ·

BIOHIT GROUP HALF YEAR FINANCIAL REPORT 2017

Biohit Oyj Half Year Financial Report 17 August 2017 at 9:30 am local time (EEST) SUMMARY January-June 2017 · Net sales grew by 6.7 % compared to H1/2016 · Net sales EUR 4.1 million (EUR 3.8 million) · Operating profit EUR 7.4 million including the profit of EUR 8.4 million booked from the joint venture exit (EUR -2.1 million) · The profit for the reporting period was EUR 7.2 million (EUR -2.1 million) · Net sales from international operations 95.0 % (90.5 %) of total net sales · Equity ratio 89.6 % (85.4 %)   PRESIDENT AND CEO SEMI KORPELA: ”During the

Powerbox releases full range of high input voltage DC/DC converters for microgrids and datacenters

Powerbox , one of Europe’s largest power supply companies and a leading force for four decades in optimizing power solutions for demanding applications, has announced a new range of high-voltage input DC/DC converters for microgrid, datacenters and industrial applications. Part of its industrial line, the new series of HVDC/DC converters operate with an input voltage range of 180VDC to 425VDC, and deliver output power levels from 150W to 750W. The range of applications powered by high-voltage DC supplies is rapidly expending, and from the latest microgrids and

Interim report – Second quarter and first half-year of 2017

Attached please find the full report as PDF file. ________________________________________________________________________________ Announcement no. 7 17 August 2017 Interim report – Second quarter and first half-year of 2017 Today, the Board of Directors approved the interim report for the second quarter and first half-year of 2017. The full report in English is attached as PDF file and contains the following highlights: · Results             Adjusted result for Q2 2017: USD -3 million (Q2 2016: USD -4 million)             - Dry Cargo: USD -7 million (USD -11

Kamux Oyj: Kamux's 40th car showroom in Finland has opened in Espoo

Kamux's 40th car showroom in Finland has opened in Espoo Kamux, a company specializing in used car sales, has opened its 40[th] car showroom in Finland. The showroom is located in Olarinluoma, Espoo. With a new showroom Kamux gains a firmer foothold on the used cars market in the metropolitan area. "With our new showroom, we are gaining an even firmer foothold on the used cars market in Finland. We already have one showroom in Espoo and a total of seven showrooms in the metropolitan area", says Jussi Mäkinen, Finnish Country Director. The location of the new showroom was chosen

Acando Interim report January 1-June 30, 2017

Second quarter April 1 – June 30, 2017 · Net sales totaled SEK 613 m (578) · Operating profit amounted to SEK 55 m (62) · The operating margin was 9.0% (10.7) · Profit after tax was SEK 41 m (62) · Earnings per share were SEK 0.40 (0.60) Accumulated January 1 – June 30, 2017 · Net sales totaled SEK 1,234 m (1,104) · Operating profit amounted to SEK 130 m (96) · The operating margin was 10.5% (8.7) · Profit after tax was SEK 95 m (86) · Earnings per share were SEK 0.93 (0.83) · Cash and cash equivalents totaled SEK 56 m (64)Statement by Carl-Magnus

Invitation to AddLife’s Capital Markets Day 6 September 2017

Hereby analysts, investors and media are welcomed to Capital Markets Day Wednesday on 6 September 2017 9:00am at Scandic Anglais, Humlegårdsgatan 23, Stockholm. Registration from 8:30am whilst coffee and sandwich will also be offered. AddLife’s CEO Kristina Willgård will speak, together with the management. The purpose of the Capital Markets Day is uppermost to portray the company’s development and further strategy as well as to present the acquisitions of the previous year. Registration is made to martin.almgren@add.life on 4 September at the latest. Should there be any questions,

Wilson Therapeutics to host conference call to provide second quarter 2017 business update

On August 24 17, 2017, at 08:00 CET, Wilson Therapeutics will publish its interim report for the second quarter 2017. All interested parties are invited to participate in a web-cast telephone conference, which will include a presentation, on the same day at 10:00 CET. The event will be hosted by Wilson Therapeutics’ CEO Jonas Hansson and CFO Anders Martin-Löf, and the presentation will be held in English.How to participateThe live webcast and a recorded on-demand version including the presentation material will be accessible at: https://tv.streamfabriken.com/wilson-therapeutics-q2-2017.

AQ Group AB (publ), interim report January - June, 2017

Second quarter, April- June 2017in brief · Net sales increased by 25% to SEK 1 077 million (860) · Operating profit (EBIT) decreased by 19 % to SEK 74 million (92) · Profit after financial items (EBT) decreased by 22 % to SEK 70 million (91) · Profit margin before tax (EBT %) 6.5% (10.6) · Cash flow from operating activities increased by 3 % to SEK 79 million (76) · Equity ratio 60 % (60) · Earnings per share after tax decreased by 23 % to SEK 3.20 (4.18) Six months, January - June 2017in brief · Net sales increased by 25% to SEK 2 079 million (1 661) ·

Catella launches “Catella Modernes Wohnen” open-ended mutual real estate fund for small-scale, affordable living

The team of Catella Real Estate AG has launched “Catella Modernes Wohnen” - an open-ended mutual real estate fund. The fund invests in small-scale, and thus affordable, accommodation with a focus on one and two person households in German conurbations.Over 75% of households in Germany are one and two person households, but one room apartments account for only 3% of Germany’s housing stock; if 2-3-room apartments are included, the share is 30%. The average residential unit size of 95 m² realised in new construction is not in line with demand. The new fund will invest in small-scale and

There are no items matching the current filter
There are no more items matching the current filter
Back to top